GlassScriptPhysician profile
Hamid Qazi
NPI 1619473162
$2,995.79
in general payments reported to CMS, 2019-2025
28 companies · $866 in 2025
The $866 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $1,043 · 2023: $290 · 2024: $374 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $416.14 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $406.17 | 2021-2024 | |
| Genzyme Corporation | $188.25 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $186.34 | 2022 | |
| Incyte Corporation | $184.99 | 2021-2022 | |
| Novo Nordisk INC | $170.68 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $162.55 | 2022-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $157.69 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Scientific Affairs, LLC | $125.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $124.38 | 2025 | Spravato |
| Janssen Biotech, INC. | $115.89 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $91.83 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $86.74 | 2022-2024 | Sotyktu |
| Kowa Pharmaceuticals America, INC. | $70.19 | 2022-2025 | Zoryve |
| Amgen INC. | $59.45 | 2023 | Prolia, Evenity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $54.94 | 2023-2024 | Freestyle Libre 3 |
| Pfizer INC. | $52.98 | 2021-2025 | |
| Hologic Sales and Service, LLC | $50.55 | 2025 | Aptima |
| Leo Pharma INC. | $49.05 | 2021-2022 | |
| Baxter Healthcare | $46.61 | 2025 | Hillrom - Volara System |
| Boston Scientific Corporation | $45.26 | 2025 | Wavewriter Alpha Prime 16 |
| Radius Health, INC. | $28.80 | 2023 | |
| Sun Pharmaceutical Industries INC. | $23.78 | 2022 | |
| Phadia US INC. | $22.83 | 2023 | Immunocap |
| Sumitomo Pharma America, INC. | $21.48 | 2025 | Gemtesa |
| Ucb, INC. | $20.74 | 2022 | |
| Epi Health, LLC | $16.85 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.63 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Qazi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.